- Führende pharmazeutische Unternehmen in Deutschland im Jahr 2015
- IMS Brogan Recognizes Quebec Health Professionals for their Contribution to the Appropriate Use of Medicines
- IMS Health Acquires TTC, Strengthening Pharma R&D Services Capabilities
- IMS Health Reports First-Quarter 2015 Results
- Phytopharmaka im Apothekenmarkt
Reuters: U.S. prescription drug spending to hit $400 billion a year by 2020: IMS
U.S. annual spending on prescription medicines will increase 22 percent over the next five years, climbing as high as $400 billion in 2020, according to a report released by health care information company IMS Health Holdings Inc on Thursday.
Bloomberg: Prescription Drug Spending Hits Record $425 Billion in U.S.
Spending on prescription drugs in the U.S. rose 12 percent to a record $425 billion before discounts last year, boosted in part by the introduction of breakthrough medicines for cancer and the growing number of patients seeking treatment for hepatitis C.
Wall Street Journal: U.S. Drug Spending Climbs
Total spending on prescription drugs in the U.S. rose 12.2% to nearly $425 billion in 2015, continuing a steep climb fueled by the introduction in recent years of expensive new drugs for cancer and infections, as well as price hikes for older drugs, according to a new report.
Associated Press: Report: US medicine spending up 8.5 percent 2015
A report from data firm IMS Health estimates patients, insurers, government programs and other payers spent a combined $309.5 billion last year on prescription medicines.
Forbes: Double-Digit Growth In Drug Spending Slows As Insurers Fight Back
Thanks to rebates and other concessions awarded by pharma companies angling to get their new products onto insurance formularies, the net spending on drugs was $310 billion in 2015, growing only 8.5% from the previous year. And the average net price for existing brands rose just 2.8%—a significantly lower rate of growth than what was seen in previous years.
- Reuters: U.S. prescription drug spending to hit $400 billion a year by 2020: IMS